|
2. Summary of Significant Accounting Policies (Details Narrative) (USD $)
|
3 Months Ended | 12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2014
|
Sep. 30, 2014
|
Jun. 30, 2014
|
Mar. 31, 2014
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|
| Net loss | $ (878,695)us-gaap_NetIncomeLoss | $ (715,774)us-gaap_NetIncomeLoss | $ (1,008,392)us-gaap_NetIncomeLoss | $ (1,403,474)us-gaap_NetIncomeLoss | $ (8,873,734)us-gaap_NetIncomeLoss | $ (1,445,125)us-gaap_NetIncomeLoss | $ (1,920,950)us-gaap_NetIncomeLoss | $ 1,582,800us-gaap_NetIncomeLoss | $ (4,006,335)us-gaap_NetIncomeLoss | $ (10,657,009)us-gaap_NetIncomeLoss | $ (13,092,387)us-gaap_NetIncomeLoss | |
| Negative cash flow from operations | (3,527,695)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | (5,912,368)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | (4,517,585)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | |||||||||
| Cash on Hand | 2,247,557us-gaap_Cash | 4,137,068us-gaap_Cash | 2,247,557us-gaap_Cash | 4,137,068us-gaap_Cash | 1,601,791us-gaap_Cash | 617,797us-gaap_Cash | ||||||
| Impairment on long-lived assets | 0us-gaap_ImpairmentOfLongLivedAssetsHeldForUse | 0us-gaap_ImpairmentOfLongLivedAssetsHeldForUse | ||||||||||
| Research and development expenses | 893,452us-gaap_ResearchAndDevelopmentExpense | 2,011,486us-gaap_ResearchAndDevelopmentExpense | 963,184us-gaap_ResearchAndDevelopmentExpense | |||||||||
| Patent costs | $ 103,434us-gaap_LicenseCosts | $ 144,326us-gaap_LicenseCosts | $ 104,150us-gaap_LicenseCosts | |||||||||
| Options | ||||||||||||
| Antidilutive shares excluded from loss per share |
21,052,030us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_StockOptionMember |
20,309,908us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_StockOptionMember |
27,278,098us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_StockOptionMember |
|||||||||
| Warrants | ||||||||||||
| Antidilutive shares excluded from loss per share |
5,692,087us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_WarrantMember |
11,763,966us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_WarrantMember |
42,205,507us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_WarrantMember |
|||||||||
| Convertible Notes | ||||||||||||
| Antidilutive shares excluded from loss per share |
509,667us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_ConvertibleDebtMember |
0us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_ConvertibleDebtMember |
0us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap_ConvertibleDebtMember |
|||||||||
| X | ||||||||||
|
- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|